Amneal Lines Up Ready-To-Use Pemetrexed Hybrid

Q1 2024 Launch Planned After FDA Approval For Pemrydi 505(b)(2) Oncology Injectable

 
• By David Wallace
  
Amneal
The FDA has approved Amneal’s Pemrydi RTU
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin